Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab with FOLFIRI and Bevacizumab in MSS Metastatic Colorectal Cancer
NCT06176885Phase 2Recruiting
- Start
- Dec 2023
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in metastatic colorectal cancer (mCRC). Started Dec 2023; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06176885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06176885.